This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Crizanlizumab for the prevention of painful crises in sickle cell disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

  • Sickle cell disease
    • is characterized by the presence of sickle hemoglobin (HbS), chronic hemolysis, recurrent pain episodes, multiorgan dysfunction, and early death

Recurrent pain episodes (called sickle cell-related pain crises or vaso-occlusive crises)

  • are the primary cause of health care encounters in patients with sickle cell disease
  • are thought to be caused by vascular occlusion in the microcirculation, increased inflammation, and alterations in nociception
  • polymerization of deoxygenated HbS distorts the shape of erythrocytes, and leads to the "sickle" appearance associated with
  • vaso-occlusion
    • is caused by the adhesion of sickle erythrocytes and leukocytes to the endothelium, which results in vascular obstruction and tissue ischemia
    • degree of sickle erythrocyte adhesion correlates with vaso-occlusion and increased severity of disease
      • activated and adherent leukocytes are the likely drivers of vaso-occlusion in collecting venules, whereas sickle erythrocytes may contribute to the occlusion of smaller vessels
      • also, platelets can bind to erythrocytes, monocytes, and neutrophils to form aggregates, which contribute to abnormalities of blood flow in patients with sickle cell disease
    • cell adhesion molecule P-selectin plays a key role in the pathogenesis of a vaso-occlusive crisis in patients with sickle cell disease
      • initiation of a vaso-occlusion is a complex event involving a multitude of molecules
        • one of the molecules involved is P-selectin, a cell adherence molecule that is rapidly and chronically expressed on the surface of endothelial cells and platelets when activated
      • process is initiated by P-selectin
        • found in storage granules of resting endothelial cells and platelets and is rapidly transferred to the cell membrane on activation of the cell during processes such as inflammation
        • is expressed on the surface of the endothelium mediates abnormal rolling and static adhesion of sickle erythrocytes to the vessel surface in vitro
          • translocation of endothelial P-selectin to the cell surface results in the prompt adhesion of sickle erythrocytes to vessels and the development of vascular occlusion in transgenic mice with sickle cell disease
          • activated platelets bind to neutrophils to form aggregates in a P-selectin-dependent manner in mice and humans with sickle cell disease
            • leukocytes are initially captured on the endothelium via P-selectin and its ligand P-selectin glycoprotein ligand 1 (PSGL-1)
            • expression of PSGL-1 by leukocytes also causes activated platelets to adhere to the leukocyte, leading to aggregate formation

Crizanlizumab is a humanized monoclonal antibody that binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1)

  • with sickle cell disease, crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises than placebo and was associated with a low incidence of adverse events (1,2)

Reference:

  • Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017;376(5):429-439. doi:10.1056/NEJMoa1611770
  • Kutlar A, Kanter J, Liles DK, Alvarez OA, Cançado RD, Friedrisch JR, Knight-Madden JM, Bruederle A, Shi M, Zhu Z, Ataga KI. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Am J Hematol. 2019 Jan;94(1):55-61. doi: 10.1002/ajh.25308. Epub 2018 Nov 25. PMID: 30295335

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.